Exposure to antibacterial agents with QT liability in 14 European countries: Trends over an 8-year period

British Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2009, Pages 88-98

  Raschi, Emanuel ^a   Poluzzi, Elisabetta ^a   Zuliani, Chiara ^a   Muller, Arno ^b   Goossens, Herman ^b   De Ponti, Fabrizio ^a,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Department of Pharmacology ^*  (Italy)

Author keywords

Antibacterial agents; Drug exposure; QT liability; Torsades de pointes

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; JOSAMYCIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SPARFLOXACIN; SPIRAMYCIN; TELITHROMYCIN;

ARTICLE; BELGIUM; DATA ANALYSIS; DENMARK; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EUROPE; FINLAND; FRANCE; GERMANY; HUMAN; ITALY; LUXEMBOURG; MEDLINE; NETHERLANDS; PHYSICIAN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; SLOVENIA; SPAIN; SWEDEN; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; DRUG UTILIZATION; ELECTROCARDIOGRAPHY; EUROPE; HUMANS;

EID: 58149109205     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03319.x     Document Type: Article

References (110)

1. De Ponti F, Poluzzi E, Montanaro NQ. T-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000 56 : 1 18.
2. ICH Topic S 7 B - The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization QT Interval Prolongation) by Human Pharmaceuticals. London : EMEA, 2005.
3. ICH Topic E 14 - The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. London : EMEA, 2005.
4. Dessertenne F Ventricular tachycardia with 2 variable opposing foci Arch Mal Coeur Vaiss 1966 59 : 263 72.
5. + channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005 25 : 133 66.
6. De Ponti F. Pharmacological and regulatory aspects of QT prolongation. In : Antitargets. Prediction and Prevention of Drug Side Effects, I edn, ed. Vaz R Klabunde T. Weinheim : Wiley-VCH, 2008 109 26.
7. Raschi E, Vasina V, Poluzzi E, de Ponti F. The hERG K(+) channel: target and antitarget strategies in drug development. Pharmacol Res 2008 57 : 181 95.
8. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006 7 : 889 908.
9. Roden DM. Taking the 'idio' out of 'idiosyncratic': predicting torsades de pointes. Pacing Clin Electrophysiol 1998 21 : 1029 34.
10. De Ponti F, Poluzzi E, Montanaro N, Ferguson JQ. Tc and psychotropic drugs. Lancet 2000 356 : 75 6.
11. De Ponti F, Poluzzi E, Vaccheri A, Bergman U, Bjerrum L, Ferguson J, Frenz KJ, McManus P, Schubert I, Selke G, Terzis-Vaslamatzis G, Montanaro N. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol 2002 54 : 171 7.
12. Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2000 45 : 557 9.
13. Iannini PB. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2001 47 : 893 4.
14. Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H. Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones. BMJ 2001 322 : 46 7.
15. Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004 64 : 1091 124.
16. Owens RC Jr., Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006 43 : 1603 11.
17. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001 57 : 185 209.
18. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol 2004 58 : 419 28.
19. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006 58 : 401 7.
20. + channel HERG. Mol Pharmacol 2001 59 : 122 6.
21. Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002 302 : 320 7.
22. Shah RR. Drugs QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 2005 28 : 1009 28.
23. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 2006 46 : 498 507.
24. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 : 1808 25.
25. Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, Mahal SK, Babb VJ. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000 20 : 317 24.
26. Monnet DL, Ferech M, Frimodt-Moller N, Goossens H. The more antibacterial trade names, the more consumption of antibacterials: a European study. Clin Infect Dis 2005 41 : 114 7.
27. Elseviers MM, Ferech M, Vander Stichele RH, Goossens H. Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf 2007 16 : 115 23.
28. Goossens H, Guillemot D, Ferech M, Schlemmer B, Costers M, van Breda M, Baker LJ, Cars O, Davey PG. National campaigns to improve antibiotic use. Eur J Clin Pharmacol 2006 62 : 373 9.
29. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998 280 : 1774 6.
30. Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007 16 : 359 65.
31. Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Saf 2007 30 : 143 55.
32. Shalviri G, Mohammad K, Majdzadeh R, Gholami K. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. Pharmacoepidemiol Drug Saf 2007 16 : 1136 40.
33. Hauben M, Patadia V, Gerrits C, Walsh L, Reich L. Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf 2005 28 : 835 42.
34. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007 18 : 243 6.
35. Huang BH, Wu CH, Hsia CP, Yin CC. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 2007 30 : 1579 82.
36. Tilelli JA, Smith KM, Pettignano R. Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy 2006 26 : 147 50.
37. Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol 2005 28 : 1221 2.
38. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006 77 : 30 2.
39. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. NZ Med J 2003 116 : U666.
40. Thomsen MB, Beekman JD, Attevelt NJ, Takahara A, Sugiyama A, Chiba K, Vos MA. No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block. Br J Pharmacol 2006 149 : 1039 48.
41. Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002 303 : 218 25.
42. Kazmierczak J, Peregud-Pogorzelska M, Rzeuski R. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol 2007 30 : 1043 6.
43. Flanagan MC, Mitchell ES, Haigney MC. Ciprofloxacin-induced torsade de pointes. Int J Cardiol 2006 113 : 239 41.
44. Daya SK, Gowda RM, Khan IA. Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis. Am J Ther 2004 11 : 77 9.
45. Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol 2006 109 : 273 4.
46. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006 11 : 52 6.
47. Prabhakar M, Krahn AD. Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm 2004 1 : 624 6.
48. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003 73 : 292 303.
49. Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant 'clinical' event? South Med J 2006 99 : 52 6.
50. Milberg P, Hilker E, Ramtin S, Cakir Y, Stypmann J, Engelen MA, Monnig G, Osada N, Breithardt G, Haverkamp W, Eckardt L. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol 2007 18 : 647 54.
51. Miyazaki H, Watanabe H, Kitayama T, Nishida M, Nishi Y, Sekiya K, Suganami H, Yamamoto K. QT PRODACT sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. J Pharmacol Sci 2005 99 : 523 9.
52. Toyoshima S, Kanno A, Kitayama T, Sekiya K, Nakai K, Haruna M, Mino T, Miyazaki H, Yano K, Yamamoto K. QT PRODACT in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 2005 99 : 459 71.
53. Hensey C, Keane D. Clarithromycin induced torsade de pointes. Ir J Med Sci 2008 177 : 67 8.
54. Vallejo CN, Rodriguez PD, Sanchez HA, Tornos Mas MP, Ribera E, Soler SJ Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection Rev Esp Cardiol 2002 55 : 878 81.
55. Germanakis I, Galanakis E, Parthenakis F, Vardas PE, Kalmanti M. Clarithromycin treatment and QT prolongation in childhood. Acta Paediatr 2006 95 : 1694 6.
56. Shi J, Chapel S, Montay G, Hardy P, Barrett JS, Sica D, Swan SK, Noveck R, Leroy B, Bhargava VO. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther 2005 43 : 123 33.
57. Stanat SJ, Carlton CG, Crumb WJ Jr., Agrawal KC, Clarkson CW. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 2003 254 : 1 7.
58. Hinterseer M, Irlbeck M, Ney L, Beckmann BM, Pfeufer A, Steinbeck G, Kaab S. Acute respiratory distress syndrome with transiently impaired left ventricular function and Torsades de Pointes arrhythmia unmasking congenital long QT syndrome in a 25-year-old woman. Br J Anaesth 2006 97 : 150 3.
59. Flyer JL. Identifying patients at risk for QT interval prolongation: case studies. J Fam Pract 2005 54 (Suppl. S18 9.
60. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004 351 : 1089 96.
61. Kyrmizakis DE, Chimona TS, Kanoupakis EM, Papadakis CE, Velegrakis GA, Helidonis ES. QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. Am J Otolaryngol 2002 23 : 303 7.
62. Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 2007 577 : 222 32.
63. Wisialowski T, Crimin K, Engtrakul J, O'Donnell J, Fermini B, Fossa AA. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 2006 318 : 352 9.
64. Duncan RS, Ridley JM, Dempsey CE, Leishman DJ, Leaney JL, Hancox JC, Witchel HJ. Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652. Biochem Biophys Res Commun 2006 341 : 500 6.
65. Guo J, Zhan S, Lees-Miller JP, Teng G, Duff HJ. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. Heart Rhythm 2005 2 : 860 6.
66. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 2004 50 : 93 101.
67. Lu HR, Vlaminckx E, Gallacher DJ. Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: beyond QT prolongation. J Pharmacol Toxicol Methods 2008 57 : 1 8.
68. Lu HR, Vlaminckx E, Teisman A, Gallacher DJ. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit. J Pharmacol Toxicol Methods 2005 52 : 90 105.
69. Hanada E, Ohtani H, Hirota M, Uemura N, Nakaya H, Kotaki H, Sato H, Yamada Y, Iga T. Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide. J Pharm Pharmacol 2003 55 : 995 1002.
70. Fteha A, Fteha E, Haq S, Kozer L, Saul B, Kassotis J. Gatifloxacin induced torsades de pointes. Pacing Clin Electrophysiol 2004 27 : 1449 50.
71. Bertino JS Jr., Owens RC Jr., Carnes, TD, Iannini PB. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002 34 : 861 3.
72. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001 21 : 1468 72.
73. Ansari SR, Chopra N. Gatifloxacin and prolonged QT interval. Am J Med Sci 2004 327 : 55 6.
74. Akita M, Shibazaki Y, Izumi M, Hiratsuka K, Sakai T, Kurosawa T, Shindo Y. Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci 2004 29 : 63 71.
75. Chiba K, Sugiyama A, Hagiwara T, Takahashi S, Takasuna K, Hashimoto K. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur J Pharmacol 2004 486 : 189 200.
76. Ball P, Mandell L, Patou G, Dankner W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004 23 : 421 9.
77. Seop KD, Kim KS, Hwan CK, Na H, Kim JI, Shin WH, Kim EJ. Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxacin and balofloxacin. Drug Chem Toxicol 2006 29 : 303 12.
78. Maxa JL, Hebeler RF, Adeeko MA. Torsades de pointes following concurrent amiodarone and levofloxacin therapy. Proc (Bayl Univ Med Cent) 2006 19 : 345 6.
79. Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005 128 : 3398 406.
80. Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H. Risk of torsades de pointes with non-cardiac drugs. BMJ 2001 322 : 46.
81. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004 75 : 242 7.
82. Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm 2003 60 : 2479 83.
83. Paltoo B, O'Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol 2001 24 : 895 7.
84. Nykamp DL, Blackmon CL, Schmidt PE, Roberson AGQ. Tc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005 39 : 543 6.
85. Basyigit I, Kahraman G, Ilgazli A, Yildiz F, Boyaci H. The effects of levofloxacin on ECG parameters and late potentials. Am J Ther 2005 12 : 407 10.
86. Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004 44 : 464 73.
87. Zunkler BJ, Claassen S, Wos-Maganga M, Rustenbeck I, Holzgrabe U. Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels. Toxicology 2006 228 : 239 48.
88. Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. Pacing Clin Electrophysiol 2005 28 : 472 3.
89. Altin T, Ozcan O, Turhan S, Ongun OA, Akyurek O, Karaoguz R, Guldal M. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 2007 23 : 907 8.
90. Dale KM, Lertsburapa K, Kluger J, White CM. Moxifloxacin and torsade de pointes. Ann Pharmacother 2007 41 : 336 40.
91. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000 59 : 115 39.
92. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005 28 : 443 52.
93. Alexandrou AJ, Duncan RS, Sullivan A, Hancox JC, Leishman DJ, Witchel HJ, Leaney JL. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 2006 147 : 905 16.
94. Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E, Engwall MJ, Zhou J. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 2005 146 : 792 9.
95. Lacroix P, Crumb WJ, Durando L, Ciottoli GB. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur J Pharmacol 2003 477 : 69 72.
96. Chaves AA, Zingaro GJ, Yordy MA, Bustard KA, O'Sullivan S, Galijatovic-Idrizbegovic A, Schuck H, Christian DB, Hoe CM, Briscoe RJ. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. J Pharmacol Toxicol Methods 2007 56 : 103 14.
97. Holzgrefe HH, Cavero I, Buchanan LV, Gill MW, Durham SK. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin. J Pharmacol Toxicol Methods 2007 55 : 227 37.
98. Keskin S, Sayali E, Temeloglu E, Gurol T, Ekizoglu I QT prolongation and ventricular tachycardia due to roxithromycin Anadolu Kardiyol Derg 2005 5 : 319 21.
99. Justo D, Mardi T, Zeltser D. Roxithromycin-induced torsades de pointes. Eur J Intern Med 2004 15 : 326 7.
100. Promphan W, Khongphatthanayothin A, Horchaiprasit K, Benjacholamas V. Roxithromycin induced torsade de pointes in a patient with complex congenital heart disease and complete atrioventricular block. Pacing Clin Electrophysiol 2003 26 : 1424 6.
101. Ahluwalia G. Torsade de pointes probably induced by sparfloxain. J Assoc Physicians India 2003 51 : 835.
102. Kakar A, Byotra SP. Torsade de pointes probably induced by sparfloxacin. J Assoc Physicians India 2002 50 : 1077 8.
103. Zunkler BJ. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol Ther 2006 112 : 12 37.
104. Terrar DA, Wilson CM, Graham SG, Bryant SM, Heath BM. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. J Pharmacol Toxicol Methods 2007 56 : 171 85.
105. Chiba K, Sugiyama A, Watanabe K, Takasuna K, Hashimoto K. Acute hypokalemia may not be an effective way to sensitize the in situ canine heart for sparfloxacin-induced long QT syndrome. J Pharmacol Sci 2006 100 : 88 92.
106. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004 44 : 689 95.
107. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005 44 : 915 34.
108. Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. Clin Ther 2005 27 : 1144 63.
109. Demolis JL, Strabach S, Vacheron F, Funck-Brentano C. Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women. Br J Clin Pharmacol 2005 60 : 120 7.
110. Demolis JL, Vacheron F, Cardus S, Funck-Brentano C. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther 2003 73 : 242 52.